Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 23;9(1):1676615. doi: 10.1080/2162402X.2019.1676615

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 5. — Treatment of patient 429–006 with cCD20-BB-ζ CAR T cells.

(a) Cytological specimen from the target malignant lymph node, Wright-Giemsa stain, magnification x100. (b) Copies of integrated CAR gene per μg of PBMC genomic DNA over time relative to infusion, as measured by qPCR. (c) Serum CAMA concentration over time measured by ELISA with mean and SD of well triplicates displayed (lower limit of detection 3.9ng/mL). (d) CD79a and CD20 surface expression among live cells in the patient’s peripheral blood and lymph node over time. (e) Annotated reference canine CD20 sequence (NCBI accession number: XP_005633357) aligned with the CD20 sequences from the patient’s neoplastic B cells pre- and day 162 post-CAR treatment.